Severe mental illness and substance misuse (dual diagnosis) - community health and social care services Cmte minutes 30/06/15

National Institute for Health and Care Excellence

## Severe mental illness and substance misuse (dual diagnosis) - community health and social care services Committee meeting

**Date:** 30/06/2015

Location: NICE Manchester offices, Bollin Room

Level 1A, City Tower, Piccadilly Plaza

Manchester M1 4BT

Minutes: Final

Committee members present:	
Alan Maryon-Davis (Chair)	(Present for notes 1 – 10)
Alyson Burberry (Expert topic member)	(Present for notes 1 – 10)
Brendan Collins (Core committee member)	(Present for notes 1 – 10)
Jo Cooke (Core committee member)	(Present for notes 1 – 10)
Jakki Cowley (Core committee member)	(Present for notes 1 – 6)
Dee Cunniffe (Expert topic member)	(Present for notes 1 – 10)
Daniela DeAngelis (Core committee member)	(Present for notes 1 – 10)
Rachel Johns (Core committee member)	(Present for notes 3 – 8)
Jane Marshall (Expert topic member)	(Present for notes 1 – 10)
Luke Mitcheson (Expert topic member)	(Present for notes 1 – 10)
Rob O'Brien (Expert topic member)	(Present for notes 1 – 10)

In attendance:		
Kay Nolan	Associate Director	(Present for notes 1 – 10)
Caroline Mulvihill	Analyst, NICE	(Present for notes 1 – 10)
Charlotte Haynes	Analyst, NICE	(Present for notes 1 – 10)
Chris Carmona	Analyst, NICE	(Present for notes 1 – 10)
Victoria Axe	Project Manager	(Present for notes 1 – 10)
Odette Megin-Viggars	Systematic reviewer (NCCMH)	(Present for notes 5 – 7)
Steve Pilling	Project Supervisor (NCCMH)	(Present for notes 1 – 10))

Observers:	
Fiona Glen	Programme Director for the Centre of Health and Social Care

Apologies:	
Richard Watt	Core Committee Member
Peter Sheath	Topic Expert Member

### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the first meeting on Severe mental illness and substance misuse (dual diagnosis) - community health and social care services. The Committee members and attendees introduced themselves.

The Chair welcomed the members of the public to the meeting. The members of the public had been briefed already, both verbally and in writing by the NICE team, and the Chair reminded them of the protocol for members of the public, whose role is to observe (they should not speak or ask questions). No filming or recording of the meeting is permitted. The Chair reminded all present that the Committee is independent and advisory, that its decisions and recommendations to NICE do not represent final NICE guidance, and that they may be changed as a result of public consultation.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- receiving a brief overview of the scope and any equality issues identified during scoping
- hearing about the plan for future meetings, including the evidence to be considered
- discussing the findings of the evidence review 1 (the epidemiology and current configuration of health and social care community services)
- developing draft recommendations and considerations
- discussing gaps in the evidence, research recommendations and expert

testimony

### 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was service organisation and delivery of wider health and social care needs of people with a severe mental illness combined with misuse of substance.

The Chair asked everyone to verbally declare any interests that they may have in regard to the matter under discussion.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Alyson Burberry	Coordinator, Royal Borough of Kensington and Chelsea	None	N/A	N/A
Brendan	Research Fellow in Health Economics, University of Liverpool/ Wirral Council	I am part of a team which has been commissioned by NICE to produce an economic evidence review and economic model for preventing drug misuse in vulnerable groups, which is for one of the other public health advisory committees (PHACs).  I am part of a team which is currently evaluating drug and alcohol treatment services for North Yorkshire County Council.	Non personal, financial, specific	Declare and participate

		In the last 12 months I have evaluated drug and alcohol treatment services for Wirral Council.		
Jo Cooke	Programme Manager, NIHR CLAHRC for South Yorkshire	The organisation I work for undertakes research in public health, self-management of long term conditions and wider determinants of health particularly working with local authorities in Yorkshire and Humber	Non personal, financial, specific	Declare and participate
Jakki Cowley	Community Core Member	None	N/A	N/A
Dee Cunniffe	Community Topic Expert Member	Policy lead for London Joint Working group for substance use in Hep C. Sponsored by Janssen, Gilead Sciences, MSD, Abbvie	Non specific, non personal, financial	Declare and participate
Daniela DeAngelis	Programme Leader, Medical Research Council	Organisation funded by MRC, connection with drug abuse and gentle drug use and drug addition. Is involved in work trying to estimate the problem of drug	Non specific, non personal, financial	Declare and participate

		use		
Rachel Johns	Deputy Director of Service Delivery, Public Health England	Husband works for and has shares in Hewlett Packard Sister works for and has shares in Proctor and Gamble Sister is a GP	Non personal, non financial, non specific	Declare and participate
Jane Marshall	Consultant Psychiatrist, Addictions CAG	None	N/A	N/A
Alan Maryon- Davis	Honorary Professor of Public Health, Kings College London, School of Medicine	Has an honorary professorial contract with Kings College London in public health. KCL might have a contractual arrangement with NICE and/or other organisations in the health and social care sectors.  A trustee of the UK Health Forum (charity). UKHF might have a contractual arrangement with NICE and/or other organisations in the health or social care sectors.  I am a trustee of Alcohol Research UK (charity). ALRUK might	Personal, non financial, non specific	

Luke	Kings College London, School of Medicine  Consultant Clinical	for the Faculty of Public Health covering a range of health issues. I also write and broadcast on health matters in a personal capacity. No conflict anticipated.  Professional Lead for	Non personal,	Declare and participate but
Alan Maryon- Davis	Honorary Professor of Public Health, Kings College	I occasionally act as a spokesperson	Personal, non financial, non specific	Declare and participate
		I am a trustee of Best Beginnings (charity). BB might have a contractual arrangement with organisations in the health or social care sectors.		
		I am a trustee of Medicinema (charity). Medicinema might have a contractual arrangement with organisations in the health or social care sectors.		
		have a contractual arrangement with NICE and/or other organisations in the health or social care sectors.		

Mitcheson	Psychologist, South London and Maudsley NHS Foundation Trust	Psychology and Psychotherapy in the South London and Maudsley NHS Foundation Trust.	financial, specific	note for any future meetings
		Clinical Advisor to Public Health England Alcohol, Drugs and Tobacco Division, Health and Wellbeing Directorate (secondment 1 day a week).		
		Honorary Senior Lecturer for Institute of Psychiatry, Psychology and Neuroscience		
		I am a lead researcher on a project funded from an untied educational grant from Reckitt Benckiser		
		NIHR funded trial – money comes to my service to pay a part of my salary: Contingency Management to reduce heroin use for people on opiate substitute treatment.		
		NIHR funded trial – (same arrangement as		

		above). RCT looking at effectiveness of naltrexone implants to prevent relapse in heroine users.		
Rob O'Brien	Clinical Nurse Specialist, Birmingham and Solihull Mental Health Foundation NHS Trust	None	N/A	N/A
Odette Megnin- Viggars	Systematic Reviewer, NCCMH	None	N/A	N/A
Steve Pilling	Project Supervisor, National Collaborating Centre for Mental Health	Funding from NICE for production of clinical guidelines. Funding from NIHR for research into treatments for substance misuse and conduct disorders, specifically John Strang and Tim Weaver in contingency management of substance misuse. Funding from NARSAD for novel treatments	Not specified by contractor	Declare and participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### 3. Overview of Scope

The Chair introduced Charlotte Haynes, Analyst at NICE, who gave a presentation on the scope of the guideline.

The Committee discussed the key aspects and key questions from the scope and were given the opportunity to ask questions.

Action: The Committee to suggest co-optees and experts who may be able to provide the current committee with further knowledge in order to draft the guideline

### 4. Equality impact assessment & related guidelines

The Chair introduced Chris Carmona, Analyst at NICE, who gave a presentation on the equality impact assessment and related guidelines.

The Committee discussed equalities in relation to the guideline and were given the opportunity to ask questions.

Action: The Committee and the NICE Team to clarify the definition of severe mental illness at the next meeting

### 5. Introduction to service delivery methods

Charlotte Haynes, Analyst at NICE, gave a presentation on the introduction to service delivery methods.

The Committee discussed service delivery methods and were given the opportunity to ask questions.

The Committee were asked to remember the following when thinking about the evidence: accessibility; acceptability; availability; appropriateness and awareness.

### 6. Overview of evidence review plan and Evidence Review 1

The Chair introduced Odette Megnin-Viggars, Systematic Reviewer with NCCMH, and Steve Pilling, Project Supervisor, NCCMH who gave an overview of the evidence review plan on severe mental illness and substance misuse (dual diagnosis) – community health and social care services. This was followed by a presentation on the Evidence Review 1.

The Committee then discussed the issues presented in relation to this guideline and took questions from the group.

The Committee thanked NCCMH for their presentations and hard work.

#### 7. General discussion

The Committee discussed the evidence they had heard in relation to this guideline and considered a number of questions.

### 8. Discussion of evidence gaps and research recommendations

The committee members were invited to identify evidence gaps and suggest ideas for addressing these, including using expert testimony. The Committee members also discussed and agreed outline areas for draft research recommendations.

The committee members identified a number of areas where expert testimony would be useful.

### 9. Summary of the day and next steps

The Chair summarised the discussion from the day and highlighted that the next meeting on this topic would take place on 22<sup>nd</sup> September 2015.

All committee members were reminded that expenses must be submitted within 3 months of a meeting taking place.

### 10. Any other business

There was no other business.

Date of next meeting: 22/09/2015

Location of next meeting: NICE Manchester offices